60 jili
60 jili
Three Greenspoon Marder Lawyers Bolster Southeast Presence MIAMI , Dec. 12, 2024 /PRNewswire/ -- Ice Miller is pleased to announce the addition of esteemed international transactional lawyers Jon Lyman and Gai Sher to help launch the firm's new Miami office . Bringing 30 years of experience counseling corporate and financial institution clients on all manner of deals, often involving cross-border transactions, Miami -based Lyman reinforces Ice Miller's strong transactional roster on both a regional and international scale, while Sher concentrates her practice on representing and providing legal counsel to startups, emerging growth companies, brands, creators, and executives in media, technology, and consumer products in all aspects of commercial transactions. Miami now joins Ice Miller's Naples office as a key component of the firm's strategy to expand its presence in South Florida and better serve clients across the Southeast region. The office will be supported by a local team that includes associate Ariela Benchlouch , as well as other Ice Miller lawyers splitting time among different offices. Reinforced by Ice Miller's national platform, Lyman is positioned to provide comprehensive guidance on mergers, acquisitions, divestitures, finance, debt, and equity offerings. Throughout his extensive career, he has regularly been called upon by directors and officers to provide legal counsel in connection with investment transactions, including for private equity, venture capital, and family office clients, as well as international debt and equity securities issues and trading compliance. Sher also counsels on all aspects of commercial transactions, while boasting experience in deal-making and structuring rights, talent, licensing, and production agreements across all facets of intellectual property, media, and entertainment. "The Miami team brings an exciting new dimension of capabilities to our clients," said Ice Miller Chief Managing Partner Michael Millikan . "They not only offer fresh and innovative legal insight, but also amplify our core strengths in dynamic new ways. Their presence in Miami aligns perfectly with our strategic growth objectives." Ice Miller Board Member and Business Group partner Tom Kesoglou also weighed in: " Miami is a key hub in the transactional landscape—critical to both our existing clients and our growth targets," he said. "Jon and Gai's strong reputations and established presence in the region, coupled with their entrepreneurial drive, position them perfectly to help the firm continue its evolution." In a supporting role, Benchlouch guides clients through complex transactions, including conducting thorough due diligence and risk assessments, drafting and negotiating key transaction documents, and navigating regulatory and compliance issues. "This team is excited to hit the ground running at Ice Miller," said Lyman. "As we've gotten to know the firm better, we've been impressed by its robust transactional platform and deep experience. The possibilities here are clear, and we see a tremendous potential for growth. I'm confident that, together, we'll continue to build on this momentum in the months and years ahead." About Ice Miller LLP Ice Miller LLP is a full-service law firm dedicated to helping our clients stay ahead in a changing world. With more than 350 legal professionals across the nation, we advise clients on all aspects of the complex legal issues impacting businesses each day. We serve private equity and venture capital funds, large private and emerging growth companies, FORTUNE 500 corporations, municipal entities, family offices, and nonprofits. To learn more, visit us at icemiller.com . View original content: https://www.prnewswire.com/news-releases/florida-based-international-transactions-team-joins-ice-miller-to-launch-new-miami-office-302330765.html SOURCE Ice Miller LLPBizarre new coffee flavour set to take cafes by storm in 2025 – but would YOU try it?
UnitedHealthcare CEO kept a low public profile. Then he was shot to death in New York'It's become uncomfortable for me': Jordan Peterson, the controversial psychologist, moves from Toronto to the U.S.
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“ Bionomics ” or the “ Company ”) is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States. Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company’s proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation (“ Neuphoria ”), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement. Voting Results In summary: 96% of the votes cast by Bionomics shareholders were in favor of the Scheme; and 87% of Bionomics shareholders present and voting (in person or by proxy, attorney or corporate representative) voted in favor of the Scheme. Next Steps Although Bionomics shareholder approval has been obtained, the Scheme remains subject to several customary conditions detailed in the Scheme Implementation Agreement, as amended and restated, between Bionomics and Neuphoria, including: the Supreme Court of New South Wales, Australia approving the Scheme at a hearing currently scheduled to occur at 3:00pm (Sydney time) on December 16, 2024 (“Second Court Hearing”); the independent expert not withdrawing or adversely modifying its conclusion that the Scheme is in the best interest of Bionomics shareholders; and the satisfaction or waiver of any remaining conditions prior to the Second Court Hearing. Subject to these remaining conditions being satisfied or waived, implementation of the Scheme is expected to occur on or about December 24, 2024 and shares of Neuphoria are expected to begin trading on Nasdaq under the symbol “NEUP” on that date or as soon as possible thereafter. For further information, please contact: About Bionomics Limited Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. Forward-Looking Statements Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics’ filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Bionomics’ website (www.bionomics.com.au) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. Not an offer of securities This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction. The Neuphoria shares have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold except in a transaction registered under the Securities Act or in a transaction exempt from, or not subject to, such registration requirements and applicable U.S. state securities laws.
How do you encapsulate a life? Helen Marie (Leland) Danielson accomplished many things during her 79 years, but her legacy is best defined by the person she was. She was a devoted daughter, a spunky younger sister, a loving wife to Russ, a caring mother to daughters Karla and Beth, a fun-loving Nanna to Vaughn, Luke, Brock and Riley, and a master relationship builder with her extended family and friends. She was a humble disciple and steward of the Lord, a trusted confidant to many and a friend to all; a gracious entertainer who used food to build fellowship. She was a Child of God. She shared her heart, tackled challenges, prayed for friends and strangers and found joy in simple things like the beauty of a flower or the uniqueness of a rock. She listened; she loved. She was a Child of God. She had an aura that drew people to her and a gift for knowing how to support those in need. God worked in her and through her and despite leaving this earth, her light continues to shine. Even in her passing, she softly encourages others to grow and strengthen their faith through her deeds and actions. She was a Child of God. We love the memory of her smile and her hilarious Nanna-isms. We appreciate the patience she showed when teaching us how to make family favorites like lefse and krumkake. We’ll miss her competitive spirit when playing games. We cherish her encouraging and loving notes (often accompanied by a newspaper clipping she thought we’d enjoy) and phone calls full of questions about our lives. We’ll miss hearing about the interactions she had with others and the joy she found caring for and connecting with people. Throughout her 15-month battle with pancreatic cancer, Helen was an inspiration to all who followed her journey. She died without fear or regret, only anticipation and excitement for God’s promise of eternal life. She was welcomed to heaven on Monday, November 18, 2024. In lieu of flowers, please consider a memorial to Helen’s preferred organizations: Bible Study Fellowship, Pulse Ministry, and Salem Evangelical Church, Moorhead. A visitation will be held at Salem Evangelical Church in Moorhead, MN, from 5:30-7:00 p.m. on Tuesday, December 17, with a time of prayer and remembrance from 7:00-8:00 p.m. A Celebration of Life will be held at Salem on Wednesday, December 18, at 11:00 a.m., with visitation one hour prior to the service. Funeral arrangements have been entrusted to the care of West Funeral Home, West Fargo, ND. An online guestbook is available at www.westfuneralhome.com.
A long-duration battery storage facility is coming to Camp Pendleton– Increased or Maintained Dividend for Over 30 Consecutive Years – GREAT NECK, N.Y., Dec. 12, 2024 (GLOBE NEWSWIRE) -- One Liberty Properties, Inc. (NYSE: OLP) today announced that its Board of Directors declared a quarterly dividend on the Company’s common stock of $0.45 per share. The dividend is payable on January 6, 2025 to stockholders of record at the close of business on December 23, 2024, and represents One Liberty’s 128 th consecutive quarterly dividend. One Liberty has increased or maintained its dividend for over 30 consecutive years. About One Liberty Properties, Inc: One Liberty is a self-administered and self-managed real estate investment trust incorporated in Maryland in 1982. The Company acquires, owns and manages a geographically diversified portfolio consisting primarily of industrial properties. Many of these properties are subject to long-term net leases under which the tenant is typically responsible for real estate taxes, insurance and ordinary maintenance and repairs. Additional financial and descriptive information on One Liberty, its operations and its portfolio, is available on its website at: http://1liberty.com. Interested parties are encouraged to review One Liberty’s Annual Report on Form 10-K and the other reports it files with the Securities and Exchange Commission for additional information. Contact: One Liberty Properties Investor Relations Phone: (516) 466-3100 http://1liberty.com
